Skip to main content
Clinical Trials/NCT01580020
NCT01580020
Completed
Phase 4

An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18)

Novartis Pharmaceuticals1 site in 1 country175 target enrollmentMay 2012

Overview

Phase
Phase 4
Intervention
RFB002
Conditions
Retinal Vein Occlusion
Sponsor
Novartis Pharmaceuticals
Enrollment
175
Locations
1
Primary Endpoint
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the initial 6-month treatment in the respective core studies CRFB002EDE17 (NCT01396057) and CRFB002EDE18 (NCT01396083).

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
October 2014
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients must have completed the core study assessments at month 6 of study CRFB002EDE17 or CRFB002EDE18, respectively

Exclusion Criteria

  • Patients who experienced an uncontrollable rise in IOP during the core study CRFB002EDE17 respectively CRFB002EDE18, i.e. IOP could not be decreased to a stable level of \< 25mmHg.
  • Use of other investigational drugs
  • Current use or likely need of systemic medications known to be toxic to the lens, retina or optic nerve
  • History of hypersensitivity to Ranibizumab or Ozurdex or any component of the ranibizumab respectively Ozurdey formulation
  • Any type of advanced, severe or unstable disease or its treatment, that could interfere with evaluations or put the patient at special risk
  • who were pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL)
  • who were menstruating and capable of becoming pregnant\* and not practicing a medically approved method of contraception (Pearl Index \<1\*\*)\*\*\* during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche was required with sufficient lead time before randomization
  • definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy
  • examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of "Deutsche Gesellschaft für Gynäkologie und Geburtshilfe":
  • Combination pill with estrogen and gestagen (no mini-pill, PI=0.1-0.9)

Arms & Interventions

Ranibizumab (Arm A)

The PRN injection scheme applied in the core study will also be followed during this extension study: Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month

Intervention: RFB002

Dexamethasone (Arm B)

A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.

Intervention: Dexamethasone

Outcomes

Primary Outcomes

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Time Frame: 6 months

The number of participants who experienced Adverse events, serious AE and death

Secondary Outcomes

  • Raw Mean Best Corrected Visual Acuity (BCVA) by Treatment Group(Baseline, 6 months and 12 months)
  • Percentage of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters at Month 12 Compared to Baseline(12 month)
  • Change in Central Subfield Thickness (CSRT) From Baseline to Month 12(Baseline , Month 12)
  • Change of Foveal Center Point Thickness (FCPT) From Baseline to Month 12(Baseline, Month 12)
  • Change in Mean Visual Function Questionnaire (VFQ-25)(Baseline, 12 months)
  • Change in SF-36 Summary Scores(Baseline, month 12)
  • Change in Euro Quality of Life Questionnaire (EQ-5D) VAS Summary Scores(Baseline, month 12)
  • Time to the First Retreatment of Both Treatment Arms(6 months)

Study Sites (1)

Loading locations...

Similar Trials